Condition

Immune Thrombocytopenia clinical trials and research

• 31Clinical trials
• 5NIH research projects
• 15Countries

Newest Immune Thrombocytopenia clinical trials

All recruiting trials (31)

• Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia

  This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.

  Recruiting Phase 2/3 Chinese SLE Treatment And Research Group · Beijing, Beijing Municipality · NCT07657793

• GL-2045 safety and blood-count help for adults with ITP

  GL-2045 is being tested in adults with immune thrombocytopenia to see if it can safely raise platelet counts like IVIg does.

  Recruiting Phase 1 Gliknik Inc. · Leeds · NCT07605845

• Eltrombopag use in adults with primary ITP: real-world patterns and outcomes

  This study looks at how eltrombopag is used in adult patients with primary ITP and what outcomes are seen in routine care.

  Recruiting Novartis · Basel · NCT07587723

• Daratumumab versus rituximab for children with primary immune thrombocytopenia

  This study will test whether daratumumab works better than rituximab to increase platelet counts in children aged 6–17 with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07362238

• Daratumumab plus rituximab for adults with relapsed or refractory immune thrombocytopenia

  This treatment combines daratumumab (an anti‑CD38 antibody) with rituximab to see if it raises platelet counts in adults with ITP who haven't responded to steroids and other therapies.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07362199

• Daratumumab versus rituximab for adult primary immune thrombocytopenia

  This trial will test whether daratumumab (an anti‑CD38 antibody) works better than rituximab for adults with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07297563

• Rituximab plus anti‑CD38 antibody versus rituximab alone for primary immune thrombocytopenia

  This trial will test whether adding an anti‑CD38 antibody (daratumumab) to rituximab helps adults with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07234019

• SHR-2173 injections for adults with primary immune thrombocytopenia.

  This will test whether multiple subcutaneous injections of SHR-2173 are safe and well tolerated in adults with primary immune thrombocytopenia and low platelet counts.

  Recruiting Phase 1 Guangdong Hengrui Pharmaceutical Co., Ltd · Wuhan, Hubei · NCT07206758

• Tafasitamab for adults with primary immune thrombocytopenia or warm autoimmune hemolytic anemia

  This trial will try tafasitamab, an anti‑CD19 antibody, in adults with primary immune thrombocytopenia or warm autoimmune hemolytic anemia to see if it is safe and helps blood counts.

  Recruiting at 39 sites Phase 2 Incyte Corporation · Glendale, Arizona and 38 other locations · NCT07104565

• Anti-CD38 antibody treatment for elderly people with primary immune thrombocytopenia

  This trial will try the anti-CD38 antibody daratumumab to raise platelet counts in people aged 60 and older with primary ITP who have not responded to multiple treatments.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07063199

• Oral rilzabrutinib for adults with immune thrombocytopenia after first-line treatment fails.

  This study will test whether the oral drug rilzabrutinib can raise and keep platelet counts up in adults with ITP who did not have lasting benefit from first-line therapy.

  Recruiting at 36 sites Phase 3 Sanofi · Clovis, California and 35 other locations · NCT07007962

• Treatment for primary immune thrombocytopenia using Anti-CD38 antibody

  This study is testing a new treatment using an antibody called Daratumumab to see if it can help people with hard-to-treat immune thrombocytopenia improve their platelet counts and reduce bleeding risks.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06838962

• Evaluating cognitive dysfunction in patients with immune thrombocytopenia

  This study is trying to see how common and serious thinking problems are in adults with immune thrombocytopenia and if these issues are linked to factors like fatigue and depression.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT06817395

• NAD (nicotinamide adenine dinucleotide) for immune thrombocytopenia (ITP)

  This trial will try NAD (nicotinamide adenine dinucleotide) to raise platelet counts in adults with persistent or relapsed ITP who did not respond to steroids and at least one second-line therapy.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06776510

• Observational study of blood clotting and bleeding disorders in Chinese patients

  This study looks at blood clotting and bleeding problems in Chinese patients to see how common they are and what factors might affect them.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality and 4 other locations · NCT06727669

• Investigating the role of inflammation markers in diagnosing immune thrombocytopenia

  This study is testing if certain inflammation markers can help doctors diagnose immune thrombocytopenia more accurately in patients aged 1 to 50.

  Recruiting Sohag University · Sohag, Sahag · NCT06715215

• Observational database for patients with immune thrombocytopenia in Brest

  This study is creating a detailed database for people with immune thrombocytopenia at the University Hospital of Brest to help improve understanding and treatment of the condition.

  Recruiting University Hospital, Brest · Brest, Brittany Region · NCT06556888

• Evaluating PRG-1801 for treating recurrent immune thrombocytopenia

  This study is testing a new CAR-T cell therapy called PRG-1801 to see if it can safely help people with recurrent immune thrombocytopenia feel better.

  Recruiting Early Phase 1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei and 1 other locations · NCT06519565

• Treatment to induce immune tolerance in ITP patients after stopping TPO-RA

  This study is testing if keeping platelet counts high in ITP patients after stopping a specific treatment can help them maintain those levels without needing more treatment.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT06478537

• Using avatrombopag to treat pediatric immune thrombocytopenia

  This study is testing if a new medication called avatrombopag can help children aged 6 to 18 with immune thrombocytopenia who didn't do well on their previous treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT06281327

• Treatment for pediatric immune thrombocytopenia using Anti-CD38 antibody

  This study is testing a new antibody treatment for children with immune thrombocytopenia who haven't had success with other therapies to see if it can help improve their condition.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06168851

• Using Obinutuzumab to treat pediatric immune thrombocytopenia

  This study is testing if Obinutuzumab can help teenagers with immune thrombocytopenia who haven't responded well to other treatments.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT06094881

• National cohort for pediatric autoimmune cytopenia

  This study is trying to gather information about children with autoimmune blood disorders to see how they do over time and what treatments work best for them.

  Recruiting at 9 sites University Hospital, Bordeaux · Amiens and 8 other locations · NCT05937828

• Evaluation of diagnosis and treatment for autoimmune cytopenias

  This study is trying to understand how autoimmune cytopenias are diagnosed and treated, looking at different tests and treatments to see what works best for patients.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT05931718

• Characterizing biological aspects of untreated ITP patients

  This study is trying to learn more about untreated primary Immune Thrombocytopenia (ITP) by looking at blood and other samples from patients who are starting their first treatment to see how their condition changes over time.

  Recruiting at 5 sites Gruppo Italiano Malattie EMatologiche dell'Adulto · Bologna and 4 other locations · NCT05694325

• Using zanubrutinib to treat immune thrombocytopenia

  This study tests if zanubrutinib can help people with immune thrombocytopenia who haven't had success with other treatments.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT05214391

• Registry for patients with Immune Thrombocytopenia and biospecimen collection

  This study is collecting health information and samples from people with Immune Thrombocytopenia to better understand the condition and improve treatment options.

  Recruiting at 63 sites Jena University Hospital · Aachen and 63 other locations · NCT05152238

• Using avatrombopag to treat adult immune thrombocytopenia with autoantibodies

  This study is testing if avatrombopag can help adults with immune thrombocytopenia who have autoantibodies and haven't had success with other treatments.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT04993885

• Evaluating anti-platelet antibodies in diagnosing autoimmune thrombocytopenia

  This study is testing if checking for specific antibodies in the blood can help doctors diagnose immune thrombocytopenia in adults with low platelet counts.

  Recruiting University Hospital, Bordeaux · Pessac · NCT04800458

• Biological bank for patients with autoimmune cytopenia

  This study is setting up a collection of biological samples from patients with autoimmune cytopenia to help researchers learn more about these conditions and find better treatments.

  Recruiting University Hospital, Bordeaux · Pessac · NCT04005638

• Registry of adult patients with immune thrombocytopenia and autoimmune hemolytic anemia in France

  This study is collecting information from adults in France who have recently been diagnosed with immune thrombocytopenia or autoimmune hemolytic anemia to better understand these conditions and how well different treatments work in real life.

  Recruiting University Hospital, Toulouse · Toulouse · NCT02877706

NIH-funded research (5)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Molecular mechanisms behind immune-related low platelets and clots in transfusion medicine

  This grant supports a team of researchers to understand how immune factors cause low platelets and abnormal clots, with a focus on transfusion medicine and pediatric to adult patients.

  NIH research Versiti Blood Health, INC. · Milwaukee, United States · NIH-11372196

• Understanding Immune Blood Disorders Affecting Platelets

  This program explores how the immune system causes low platelet counts and blood clots in people of all ages, from newborns to adults.

  NIH research Versiti Blood Health, INC. · Milwaukee, United States · NIH-11158635

• Developing a new treatment for immune thrombocytopenia using a specialized enzyme

  This study is testing a new treatment for people with immune thrombocytopenia (ITP) that uses a specially designed enzyme to help reduce harmful antibodies and improve platelet counts, aiming to provide a safer and more effective option than what’s currently available.

  NIH research Cyrus Biotechnology, INC. · Seattle, United States · NIH-11069861

• Understanding how platelet strength relates to bleeding risk in immune thrombocytopenia

  This study is looking at how strong individual platelets are in people with immune thrombocytopenic purpura (ITP) to see if that can help doctors figure out who might be at a higher risk for bleeding and need treatment, so they can avoid giving unnecessary treatment to those who are less at risk.

  NIH research Emory University · Atlanta, United States · NIH-11042700

• Understanding how immune responses affect blood platelet levels

  This study is looking into how the immune system affects low platelet counts and blood clotting issues, with the goal of finding better treatments for people of all ages, from newborns to adults.

  NIH research Versiti Wisconsin, INC. · Milwaukee, United States · NIH-10934140

Related topics

Quick answers

How many Immune Thrombocytopenia clinical trials are recruiting right now?

31, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 15 countries. The most sites are in China (17 trials), France (7 trials), Italy (4 trials), United States (3 trials), United Kingdom (2 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 13, Phase 1: 2, Phase 2/3: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →